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Abstract
Enchondromas are common intraosseous, usually benign cartilaginous tumors, that develop in
close proximity to growth plate cartilage. When multiple enchondromas are present, the condition
is called enchondromatosis also known as Ollier disease (WHO terminology). The estimated
prevalence of Ollier disease is 1/100,000. Clinical manifestations often appear in the first decade of
life. Ollier disease is characterized by an asymmetric distribution of cartilage lesions and these can
be extremely variable (in terms of size, number, location, evolution of enchondromas, age of onset
and of diagnosis, requirement for surgery). Clinical problems caused by enchondromas include
skeletal deformities, limb-length discrepancy, and the potential risk for malignant change to
chondrosarcoma. The condition in which multiple enchondromatosis is associated with soft tissue
hemangiomas is known as Maffucci syndrome. Until now both Ollier disease and Maffucci syndrome
have only occurred in isolated patients and not familial. It remains uncertain whether the disorder
is caused by a single gene defect or by combinations of (germ-line and/or somatic) mutations. The
diagnosis is based on clinical and conventional radiological evaluations. Histological analysis has a
limited role and is mainly used if malignancy is suspected. There is no medical treatment for
enchondromatosis. Surgery is indicated in case of complications (pathological fractures, growth
defect, malignant transformation). The prognosis for Ollier disease is difficult to assess. As is
generally the case, forms with an early onset appear more severe. Enchondromas in Ollier disease







Enchondromas are common benign usually asympto-
matic cartilage tumors, which develop in the metaphyses
and may become incorporated into the diaphyses of long
tubular bones, in close proximity to growth plate cartilage
[1-3]. Enchondromatosis (OMIM 166000) or Ollier dis-
ease (World Health Organization terminology) [4] is
defined by the presence multiple enchondromas and
characterized by an asymmetric distribution of cartilage
lesions that can be extremely variable (in terms of size,
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number, location, evolution of enchondromas, age of
onset and of diagnosis, requirement for surgery).
The condition in which multiple enchondromatosis is
associated with soft tissue hemangiomas is known as Maf-
fucci syndrome.
Epidemiology
The estimated prevalence of Ollier disease is 1/100,000.
Clinical description
Clinical manifestations in Ollier disease often appear in
the first decade of life and usually start with the appear-
ance of palpable bony masses on a finger or a toe, an asy-
metric shortening of an extremity with limping, osseous
deformities associated or not with pathologic fractures [1-
3]. Upon physical examination, enchondromas present
on the extremities are usually visible as masses embedded
within phalanges, metacarpal and metatarsal bones.
Enchondromas frequently affect the long tubular bones,
particularly the tibia, the femur, and/or the fibula; flat
bones, especially the pelvis, can also be affected. The
lesions may affect multiple bones and are usually asymet-
rically distributed, exclusively or predominantly affecting
one side of the body. Affected bones are often shortened
and deformed. Indeed, bone shortening may be the only
clinical sign of the disease. These bone shortenings are
often associated with bone bending and curving, and may
lead to limitations in articular movement. Forearm
deformities are frequently encountered and these are sim-
ilar to those observed in hereditary multiple exostosis
(HME). The trunc is usually not affected, except for rib
enchondromas and scoliosis resulting from pelvis imbal-
ance. In childhood, the lesions are subjected to pathologic
fractures.
Clinical forms
While enchondromatosis had been recognized for a long
time, Ollier at the end of the 19th century (thus the name
of Ollier's or Ollier disease to designate the condition)
emphasized the asymetrical and random distribution of
enchondromas. Some authors distinguish two subtypes of
enchondromatosis, enchondromatosis and Ollier disease.
The first form affects mostly men. It is characterized by
enchondromas located mainly at the extremities and
appears to be transmitted in an autosomal dominant fash-
ion [5]. The second form affects mostly women. It is char-
acterized by an unilateral distribution of enchondromas
and appears sporadic. However, the basis for this classifi-
cation into two forms is not supported by a thorough
analysis of available clinical reports. In all instances, the
association of multiple enchondromas with hemangi-
omas is referred to as Maffucci syndrome. Recently, a pre-
viously unreported form in which there is extensive
involvement of the epiphyseal and metaphyseal regions
of long bones of the lower extremity has been described
[6].
Radiography
Enchondromas are rarely observed at birth, although the
lesions are most likely already present. Roentgenograms
typically show multiple, radiolucent, homogenous
lesions with an oval or elongated shape and well defined
slightly thickened bony margin [1-3]. The lesions and
long bone axis run parallel (Figure 1). The lesions usually
calcify with time and become diffusely punctated or stip-
pled, a light trabeculation may be visible. Enchondromas
are frequently assembled as clusters, thus resulting in the
metaphyseal widening. When localized at the bone bor-
der, the enchondromas produce a typical notch-like
image. A minor delay in bone age, on average 0.6 +/- 1.3
years, has been reported in children affected by Ollier dis-
ease [7].
Enchondromas are almost exclusively localized in the
metaphysis of long bones and in the small bones of the
hands and feet. They are initially localized close to the
growth plate cartilage and then migrate progressively
towards the diaphysis. The epiphyseal region next to an
affected metaphysis may show irregularities [1,6].
Again, it is important to emphasize the irregular distribu-
tion of the lesions, which can be localized to one limb, or
limited to one half of the body; however, even limited
largely to one side of the body, one or two enchondromas
are frequently present on the other side, in particular in
the hand bones. If lesions are distributed over the entire
body, one side is typically more affected. In the hands, the
lesions almost never affect all metacarpal bones and
phalanges.
Enchondromas result in severe growth abnormalities
(more severe than those observed in multiple exostosis).
Affected diaphysis are short and massively enlarged, and
these may show bending close to the metaphysis. Ulnar
shortening is usually more relevant than shortening of the
radius; fingers often show irregular sizes. Signs of patho-
logical fractures may be present.
Signs of malignant transformation should be looked for,
as it is a major complication of enchondromatosis. These
signs include cortical erosion, extension of the tumor into
soft tissues, and irregularity or indistinctness of the surface
of the tumor. Indeed, enchondromas tend to be well cir-
cumscribed, whereas chondrosarcomas show poor
demarcation. The pattern of mineralization is also impor-
tant in differentiating enchondromas from chondrosarco-
mas. As mentioned above, enchondromas tend to show a
uniform pattern of mineralization, and the presence of
unmineralized parts in the lesion is suspicious.Orphanet Journal of Rare Diseases 2006, 1:37 http://www.OJRD.com/content/1/1/37
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Roentgenographs showing enchondromas localized in the upper part of the humerus (fig 1a and lower part of the radius (fig  1b) of a girl 7 years of age affected with Ollier disease Figure 1
Roentgenographs showing enchondromas localized in the upper part of the humerus (fig 1a and lower part of the radius (fig 
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Histopathology
Macroscopic examination of enchondromas usually
shows multiple oval-shaped or round cartilaginous nod-
ules in osseous portions of bone [1,2]. The individual
nodules are limited at their periphery by woven or lamel-
lar bone, and are separated from each other by inter-
trabecular marrow spaces. The cartilaginous tumor matrix
is usually solid, with myxoid changes, which manifest as
frayings of the matrix. Enchondromas are characterized by
the presence of a striking heterogeneity and diversity in
the degree of cellularity and chondrocyte phenotype. This
heterogeneity depends to some extent on factors such as
localization and the patient's age. In part due to this
important cellular heterogeneity, the distinction between
benign enchondromas and malignant chondrosarcomas
by histochemical criteria is difficult. The histological crite-
ria for malignancy that are used for conventional chond-
rosarcoma can not be used in Ollier disease because of the
increased cellularity, and therefore the distinction
between enchondroma and grade I chondrosarcoma in
the context of enchondromatosis is extremely difficult or
even impossible. The diagnosis therefore relies on the
combination of radiographical (cortical destruction, soft
tissue extension), clinical and histological criteria.
Etiology and pathogenesis
Endochondral bone ossification is a highly regulated
process, which requires the progression of undifferenti-
ated mesenchymal cells into hypertrophic chondrocytes
and the subsequent replacement of a cartilaginous matrix
by mineralized bone [8,9]. Enchondromas develop in the
metaphysis of long tubular bones in close proximity to the
growth plate. Consequently, it was proposed that they
result from abnormalities in signaling pathways control-
ling the proliferation and differentiation of chondrocytes,
leading to the development of intraosseous cartilaginous
foci.
Genetics
Ollier disease – and Maffucci syndrome – are usually non-
familial disorders [1-3], and both disorders thus appear to
occur spontaneously and are not inherited. The irregular
distribution of the lesions in Ollier disease strongly sug-
gests that it is a disorder of endochondral bone formation
that occurs due to a post-zygotic somatic mutation that
results in mosaism. In two instances, enchondromatosis
has been observed in the sons of fathers who presented
with mild skeletal dysplasia but without evidence of
enchondromas [5,10]. In one of these cases, a hetero-
zygous mutation (R150C) in the PTH/PTHrP receptor
(PTHR1 gene) was inherited from the father [10].
Parathyroid hormone-related protein (PTHrP) and Indian
Hedgehog (IHH) acting on their respective receptors
PTHR1 and PTCH1 exert a tightly coupled signaling relay,
which is critical for the regulation of endochondral ossifi-
cation (Figure 2). A mutant PTHR1 (R150C) was found to
be expressed in the enchondromas from two of six unre-
lated patients with enchondromatosis [10]. The mutation
was found on one parental allele in one patient and his
father, who presented with atypical mild skeletal dyspla-
sia, but not with enchondromatosis. However, neither the
R150C mutation (26 tumors) nor any other mutation in
the  PTHR1  gene (11 patients) could be identified in
another study, suggesting heterogeneity of the molecular
defect(s) leading to enchondromatosis [11].
The mutant PTHR1 (R150C) seems to constitutively acti-
vate the PTHrP-dependent pathway, thus decreasing
chondrocyte differentiation, thereby leading to the forma-
tion of enchondromas [10]. Consistent with this conclu-
sion, transgenic mice expressing the mutant PTHR1 under
the control of the collagen type II promoter develop
tumors that are similar to those observed in human
enchondromatosis. Because regulation of Ihh by PTHrP
was found to be lost in these enchondromas, additional
transgenic mice were generated that overexpress the
Hedgehog (Hh) transcriptional regulator, Gli2. These
Importance of IHH and PTHrP signaling in the modulation of  chondrocyte proliferation and differentiation during endo- chondral bone formation Figure 2
Importance of IHH and PTHrP signaling in the modulation of 
chondrocyte proliferation and differentiation during endo-
chondral bone formation. PTHrP is synthesized by chondro-
cytes and perichondrial cells in the periarticular growth plate. 
PTHrP diffuses toward the prehypertrohic zone where it 
binds to and activates its receptor, the PTHR1, and thereby 
maintains chondrocyte proliferation and delays chondrocyte 
differentiation into pre-hypertrophic and hypertrophic 
chondrocytes. After chondrocytes stop proliferating at the 
transition from a proliferating into a hypertrophic phenotype, 
they synthesize IHH. IHH acts to indirectly increase the syn-
thesis of PTHrP. IHH and PTHrP thus participate in a nega-
tive feed-back loop that serves to regulate the rate and 
synchrony of growth plate chondrocytes. Besides increasing 
PTHrP synthesis, IHH also stimulates, both directly and indi-
rectly, chondrocyte proliferation and inhibits their terminal 
differentiation. Parathyroid hormone-related protein 
(PTHrP)  Indian Hedgehog (IHH)  Parathyroid hormone 
receptor 1 (PTHR1)  Orphanet Journal of Rare Diseases 2006, 1:37 http://www.OJRD.com/content/1/1/37
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mice develop ectopic cartilaginous islands similar to those
observed in the mice expressing the mutant PTHR1. Thus,
the Ihh signaling pathway as a whole seems to play a cru-
cial role in the formation of enchondromatosis.
Cytogenetics and molecular genetics
There are few cytogenetic reports of benign enchondro-
mas, but there are no tumor-specific chromosomes or
chromosomal regions associated with enchondromas, or
chondrosarcomas [12-15].
Little is known about the molecular mechanisms involved
in the malignant transformation from enchondromas to
chondrosarcomas. Expression of PTHrP, the PTHR1, and
their downstream partner Bcl2 may be correlated with the
grade of malignancy in chondrosarcoma [16-19].
Diagnostic methods
The diagnosis of Ollier disease is based on clinical and
conventional radiological evaluations. Histological analy-
sis has a limited role and is mainly used if malignancy is
suspected. Additional investigations, such as scintigraphy,
ultrasound, magnetic resonance imaging (MRI) are not
useful for establishing the diagnosis. They are indicated
for the evaluation and surveillance of lesions that become
symptomatic (pain, increase in size).
Differential diagnosis
Ollier disease must be differentiated from HME [1-3].
HME is an autosomal dominant disorder characterized by
multiple bone tumors capped by cartilage, that occur
mostly in the metaphyses of long bones. To establish the
diagnosis of either disease, clinical and radiological crite-
ria are used. The most important criterium to distinguish
enchondromas from osteochondromas as seen in HME is
the localization of bone lesions: osteochondromas are
located at the bone surface and enchondromas are located
in the center of bones, thus allowing radiographic distinc-
tion.
Other rare forms of chondromatosis, which include met-
achondromatosis, spondyloenchondroplasia and geno-
chondromatosis type I and II, are described and have been
well defined [1].
Genetic counseling
Ollier disease – and Maffucci syndrome – are usually spo-
radic, non-familial disorders.
Treatment
There is no medical treatment for Ollier disease. Surgery is
indicated in case of complications (pathological fractures,
growth defect, malignant transformation).
Prognosis
The prognosis of Ollier disease is difficult to assess [1].
Patient with numerous lesions may have a better progno-
sis than patients with localized cartilaginous changes,
which may induce major shortening of a lower extremity
and thus limb asymmetry, especially if already present in
a very young child. Similarly, early development of
enchondromas in phalanges may lead to major finger
deformities. As is generally the case, forms with an early
onset appear more severe. Neural compressions are less
frequently observed than in HME. Enchondromas in
Ollier disease present a risk of malignant transformation
of enchondromas into chondrosarcomas, which usually
occurs in young adults, and thus at an earlier age than
observed in patients with chondrosarcoma alone. The
reported incidence of malignant transformation is varia-
ble and estimated to occur in 5–50% of the cases [3,20-
22]. It is higher in Maffucci's syndrome, the prognosis of
which is more severe than that of Ollier disease [1,2].
Association of Ollier disease with other tumors has been
reported [1,23-25].
Unresolved questions
￿ Although an identical heterozygous mutation in the
PTHR1 gene has been identified in two unrelated patients
with Ollier disease, this or other mutations in this gene
were not identified in additional patients with this disor-
der. Although these studies need to be extended, they sug-
gest that the cause of Ollier disease is heterogenous and
raise the possibility that two (or more) genetic mutations
are required to develop the disease. The development of
enchondromas could thus be caused by a germline muta-
tion associated with a somatic mosaic mutation. Further-
more, additional mutational events may underly
progression from enchondromas to tumors.
￿ The molecular mechanisms involved in malignant trans-
formation are unknown.
￿ The link, if any, between Ollier disease and Maffucci
syndrome is unknown.
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